Previous close | 2,126.00 |
Open | 2,121.00 |
Bid | 2,084.00 x N/A |
Ask | 2,085.00 x N/A |
Day's range | 2,074.00 - 2,131.00 |
52-week range | 1,825.00 - 2,947.00 |
Volume | |
Avg. volume | 132,787 |
Market cap | 135.838B |
Beta (5Y monthly) | 0.76 |
PE ratio (TTM) | 31.55 |
EPS (TTM) | 66.06 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 2,667.91 |
Company Announcement COPENHAGEN, Denmark; March 25, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from March 18, 2024 to March 22, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK) March 18, 2024XCSE7,7532,051.78
Company Announcement COPENHAGEN, Denmark; March 18, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 15, 2024 On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program was expected to be completed no later than March 15, 2024, and comprised up to 190,000 shares. The following transactions were executed under the program from M
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]